Microtubule Inhibitors and Cardiotoxicity

Amogh M Joshi; George S Prousi; Christopher Bianco; Midhun Malla; Avirup Guha; Mahek Shah; Sherry-Ann Brown; Brijesh Patel

doi:10.1007/s11912-021-01014-0

Microtubule Inhibitors and Cardiotoxicity

Amogh M Joshi, George S Prousi, Christopher Bianco, Midhun Malla, Avirup Guha, Mahek Shah, Sherry-Ann Brown, Brijesh Patel

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

PURPOSE OF REVIEW: Cancer and heart disease are the leading causes of mortality in the USA. Advances in cancer therapies, namely, the development and use of chemotherapeutic agents alone or in combination, are becoming increasingly prevalent.

RECENT FINDINGS: Many chemotherapeutic agents have been associated with adverse cardiovascular manifestations. The mechanisms of these sequelae remain incompletely understood. In particular, microtubule inhibitor (MTI) agents have been related to the development of heart failure, myocardial ischemia, and conduction abnormalities. At present, there are no guidelines for patients undergoing MTI therapy as it pertains to both preventative and mitigatory strategies for cardiovascular complications. We conducted a literature review focusing on content related to the use of MTIs and their effect on the cardiovascular system. MTIs have been associated with various forms of cardiotoxicity, and fatal cardiotoxicities are rare. The most well-described cardiotoxicities are brady- and tachyarrhythmias. The co-administration of anthracycline-based agents with MTIs can increase the risk of cardiotoxicity.

Original language	English (US)
Pages (from-to)	30
Journal	Current Oncology Reports
Volume	23
Issue number	3
DOIs	https://doi.org/10.1007/s11912-021-01014-0
State	Published - Feb 13 2021
Externally published	Yes

Keywords

Cardiotoxicity/etiology
Heart Diseases/chemically induced
Humans
Neoplasms/drug therapy
Tubulin Modulators/adverse effects

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11912-021-01014-0

Cite this

@article{d9a5859a35754d94877a02124e871737,

title = "Microtubule Inhibitors and Cardiotoxicity",

abstract = "PURPOSE OF REVIEW: Cancer and heart disease are the leading causes of mortality in the USA. Advances in cancer therapies, namely, the development and use of chemotherapeutic agents alone or in combination, are becoming increasingly prevalent.RECENT FINDINGS: Many chemotherapeutic agents have been associated with adverse cardiovascular manifestations. The mechanisms of these sequelae remain incompletely understood. In particular, microtubule inhibitor (MTI) agents have been related to the development of heart failure, myocardial ischemia, and conduction abnormalities. At present, there are no guidelines for patients undergoing MTI therapy as it pertains to both preventative and mitigatory strategies for cardiovascular complications. We conducted a literature review focusing on content related to the use of MTIs and their effect on the cardiovascular system. MTIs have been associated with various forms of cardiotoxicity, and fatal cardiotoxicities are rare. The most well-described cardiotoxicities are brady- and tachyarrhythmias. The co-administration of anthracycline-based agents with MTIs can increase the risk of cardiotoxicity.",

keywords = "Cardiotoxicity/etiology, Heart Diseases/chemically induced, Humans, Neoplasms/drug therapy, Tubulin Modulators/adverse effects",

author = "Joshi, {Amogh M} and Prousi, {George S} and Christopher Bianco and Midhun Malla and Avirup Guha and Mahek Shah and Sherry-Ann Brown and Brijesh Patel",

year = "2021",

month = feb,

day = "13",

doi = "10.1007/s11912-021-01014-0",

language = "English (US)",

volume = "23",

pages = "30",

journal = "Current Oncology Reports",

issn = "1523-3790",

publisher = "Current Science, Inc.",

number = "3",

}

TY - JOUR

T1 - Microtubule Inhibitors and Cardiotoxicity

AU - Joshi, Amogh M

AU - Prousi, George S

AU - Bianco, Christopher

AU - Malla, Midhun

AU - Guha, Avirup

AU - Shah, Mahek

AU - Brown, Sherry-Ann

AU - Patel, Brijesh

PY - 2021/2/13

Y1 - 2021/2/13

N2 - PURPOSE OF REVIEW: Cancer and heart disease are the leading causes of mortality in the USA. Advances in cancer therapies, namely, the development and use of chemotherapeutic agents alone or in combination, are becoming increasingly prevalent.RECENT FINDINGS: Many chemotherapeutic agents have been associated with adverse cardiovascular manifestations. The mechanisms of these sequelae remain incompletely understood. In particular, microtubule inhibitor (MTI) agents have been related to the development of heart failure, myocardial ischemia, and conduction abnormalities. At present, there are no guidelines for patients undergoing MTI therapy as it pertains to both preventative and mitigatory strategies for cardiovascular complications. We conducted a literature review focusing on content related to the use of MTIs and their effect on the cardiovascular system. MTIs have been associated with various forms of cardiotoxicity, and fatal cardiotoxicities are rare. The most well-described cardiotoxicities are brady- and tachyarrhythmias. The co-administration of anthracycline-based agents with MTIs can increase the risk of cardiotoxicity.

AB - PURPOSE OF REVIEW: Cancer and heart disease are the leading causes of mortality in the USA. Advances in cancer therapies, namely, the development and use of chemotherapeutic agents alone or in combination, are becoming increasingly prevalent.RECENT FINDINGS: Many chemotherapeutic agents have been associated with adverse cardiovascular manifestations. The mechanisms of these sequelae remain incompletely understood. In particular, microtubule inhibitor (MTI) agents have been related to the development of heart failure, myocardial ischemia, and conduction abnormalities. At present, there are no guidelines for patients undergoing MTI therapy as it pertains to both preventative and mitigatory strategies for cardiovascular complications. We conducted a literature review focusing on content related to the use of MTIs and their effect on the cardiovascular system. MTIs have been associated with various forms of cardiotoxicity, and fatal cardiotoxicities are rare. The most well-described cardiotoxicities are brady- and tachyarrhythmias. The co-administration of anthracycline-based agents with MTIs can increase the risk of cardiotoxicity.

KW - Cardiotoxicity/etiology

KW - Heart Diseases/chemically induced

KW - Humans

KW - Neoplasms/drug therapy

KW - Tubulin Modulators/adverse effects

U2 - 10.1007/s11912-021-01014-0

DO - 10.1007/s11912-021-01014-0

M3 - Review article

C2 - 33582937

SN - 1523-3790

VL - 23

SP - 30

JO - Current Oncology Reports

JF - Current Oncology Reports

IS - 3

ER -

Microtubule Inhibitors and Cardiotoxicity

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this